Transdermal drug delivery has, in recent years, attracted considerable interest. However, despite the obvious advantages of this novel route of drug administration to achieve systemic therapeutic effect, there remain important, and sometimes severe, limitations on the physiochemical and pharmacological properties of the agent to be delivered. This article reviews the present status and accomplishments of transdermal drug delivery. The benefits, disadvantages, and, as yet, unresolved problems inherent to drug input via the skin are addressed. Deficiencies in our knowledge of the percutaneous absorption process in man are identified, and approaches to elucidate these unknowns are discussed. Finally, with respect to the future potential of transdermal drug delivery, experimental and modeling techniques, which can be employed to assess the feasibility and promise of a therapeutic candidate, are described and illustrated with pertinent examples.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of testosterone treatment during puberty in boys with Klinefelter syndrome (The TIPY Study): protocol for a nationwide randomised, double-blinded, placebo-controlled study.
BMJ Open
March 2025
Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Introduction: Klinefelter syndrome (KS) is a genetic condition characterised by the presence of an extra X chromosome in males (47,XXY). KS is associated with various phenotypic characteristics in adult life, including infertility, hypogonadism and increased risk of type II diabetes, cardiovascular disease and osteoporosis. Additionally, individuals with KS often experience mental health challenges and functional impairments that significantly impact their quality of life.
View Article and Find Full Text PDFDevelopment of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson's Disease.
Eur J Drug Metab Pharmacokinet
March 2025
College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si, Jeollanam-do, 57922, Republic of Korea.
Background And Objective: Rotigotine, a dopamine agonist, is used to treat Parkinson's disease and restless leg syndrome, with transdermal patches being the primary delivery method in clinical practice. However, quantitative information on the in vivo pharmacokinetics of rotigotine across various dosage regimens via transdermal administration remains limited, and this has been identified as a significant barrier to achieving precision medicine. This study aims to develop a novel physiologically-based systematic pharmacokinetic model tailored to rotigotine transdermal drug delivery.
View Article and Find Full Text PDFSalutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and hypertension.
Geroscience
March 2025
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.
Geroscience has helped to usher in a new and exciting era of aging drug development and evaluation of novel and repurposed agents, as well as natural compounds purported to target one or more aging hallmarks. Among the latter, curcumin has long been pursued as a promising strategy but has failed to provide convincing evidence in human trials. Oral intake is the typical route of administration tested for the vast majority of gerotherapeutic candidates, including curcumin, but efficacy is dependent upon good oral bioavailability and pharmacokinetics.
View Article and Find Full Text PDFTemperature-dependent phase transition microemulsions for enhanced transdermal delivery of finasteride and silodosin.
Sci Rep
March 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Finasteride and silodosin are potential combinations for management of benign prostatic hyperplasia (BPH). Simultaneous transdermal delivery can overcome reasons of their poor oral bioavailability. This was achieved via menthol-based microemulsion (ME) which can undergo thermoresponsive phase transition.
View Article and Find Full Text PDFDissolving microneedles for brain delivery: Recent advances and challenges.
Drug Discov Today
March 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India; Sunway Biofunctional Molecules Discovery Centre (SBMDC), School of Medical and Life Sciences, Sunway University, Sunway, Malaysia. Electronic address:
Over the past decade, dissolving microneedles (DMNs) have emerged as a promising approach for drug delivery to the brain. They are tiny devices designed to penetrate biological barriers, offering a painless method for localized and controlled drug delivery. They are suitable for delivering drugs that are susceptible to degradation when delivered orally.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!